Overview

• Kirti Ganorkar will assume the managing director role on September 1, 2025, succeeding founder Dilip Shanghvi
• Dilip Shanghvi will transition to executive chairman, retaining the board chair and guiding the company’s specialty portfolio strategy
• Abhay Gandhi, president and CEO of North America, is departing Sun Pharma and Richard Ascroft will take over that division
• Ganorkar has headed the India business since June 2019 and drove Sun Pharma’s specialty push by securing Ilumya rights and spearheading entries into Japan and Europe
• The changes are part of a structured succession plan aimed at ensuring leadership continuity and leveraging internal talent